Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CIRM funds City of Hope to develop T cell-based therapy
The grant will support the development of a T cell-based immunotherapy that re-directs patient’s immune response against glioma stem cells for the treatment of cancer. In the research,
The grant will support the development of a T cell-based immunotherapy that re-directs patient’s immune response against glioma stem cells for the treatment of cancer. In the research,
The orphan drug status offers seven years marketing exclusivity from the time of approval and provides benefits such as tax incentives, reduced user fees and assistance for the
Synera uses Nuvo’s Controlled Heat Assisted Drug Delivery (CHADD) technology. As per the terms of the agreements, Nuvo will receive a double digit royalty on net sales of
Genmab gained the payment from GlaxoSmithKline which was triggered by the NDA submission of Arzerra. The application seeks approval for the treatment of patients with chronic lymphocytic leukemia
Fycompa (perampanel) is an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. Perampanel is a highly
The study is designed to evaluate how MIV-711 affects biomarkers known to be relevant for measuring bone and cartilage turnover and the therapeutic dose levels to be used
The pharmaceutical companies, which have been engaged in the production of these drugs, were issued notices and have been directed to rectify the manufacturing processes, the pharmabiz reported.
As per the agreement, Takeda Brazil will take over Multilab for BRL500m upfront and up to BRL40m in additional future milestone payments to the owners of Multilab. The
The Phase 1 dose-escalating clinical trial in healthy volunteers is designed to assess whether the aqueous formulation of SMT C1100 can provide the consistent levels of drug in
As per the agreement, Ranbaxy will pay royalties on net sales of Absorica to Cipher. Ranbaxy Americas senior vice president and regional director Venkat Krishnan said, "Absorica is